IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0269192.html
   My bibliography  Save this article

Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data

Author

Listed:
  • Caroline S Clarke
  • Rachael M Hunter
  • Andrea Gabrio
  • Christopher D Brawley
  • Fiona C Ingleby
  • David P Dearnaley
  • David Matheson
  • Gerhardt Attard
  • Hannah L Rush
  • Rob J Jones
  • William Cross
  • Chris Parker
  • J Martin Russell
  • Robin Millman
  • Silke Gillessen
  • Zafar Malik
  • Jason F Lester
  • James Wylie
  • Noel W Clarke
  • Mahesh K B Parmar
  • Matthew R Sydes
  • Nicholas D James

Abstract

Adding abiraterone acetate (AA) plus prednisolone (P) to standard of care (SOC) improves survival in newly diagnosed advanced prostate cancer (PC) patients starting hormone therapy. Our objective was to determine the value for money to the English National Health Service (NHS) of adding AAP to SOC. We used a decision analytic model to evaluate cost-effectiveness of providing AAP in the English NHS. Between 2011–2014, the STAMPEDE trial recruited 1917 men with high-risk localised, locally advanced, recurrent or metastatic PC starting first-line androgen-deprivation therapy (ADT), and they were randomised to receive SOC plus AAP, or SOC alone. Lifetime costs and quality-adjusted life-years (QALYs) were estimated using STAMPEDE trial data supplemented with literature data where necessary, adjusting for baseline patient and disease characteristics. British National Formulary (BNF) prices (£98/day) were applied for AAP. Costs and outcomes were discounted at 3.5%/year. AAP was not cost-effective. The incremental cost-effectiveness ratio (ICER) was £149,748/QALY gained in the non-metastatic (M0) subgroup, with 2.4% probability of being cost-effective at NICE’s £30,000/QALY threshold; and the metastatic (M1) subgroup had an ICER of £47,503/QALY gained, with 12.0% probability of being cost-effective. Scenario analysis suggested AAP could be cost-effective in M1 patients if priced below £62/day, or below £28/day in the M0 subgroup. AAP could dominate SOC in the M0 subgroup with price below £11/day. AAP is effective for non-metastatic and metastatic disease but is not cost-effective when using the BNF price. AAP currently only has UK approval for use in a subset of M1 patients. The actual price currently paid by the English NHS for abiraterone acetate is unknown. Broadening AAP’s indication and having a daily cost below the thresholds described above is recommended, given AAP improves survival in both subgroups and its cost-saving potential in M0 subgroup.

Suggested Citation

  • Caroline S Clarke & Rachael M Hunter & Andrea Gabrio & Christopher D Brawley & Fiona C Ingleby & David P Dearnaley & David Matheson & Gerhardt Attard & Hannah L Rush & Rob J Jones & William Cross & Ch, 2022. "Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on S," PLOS ONE, Public Library of Science, vol. 17(6), pages 1-17, June.
    • Handle: RePEc:plo:pone00:0269192
    DOI: 10.1371/journal.pone.0269192
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0269192
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0269192&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0269192?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. van Buuren, Stef & Groothuis-Oudshoorn, Karin, 2011. "mice: Multivariate Imputation by Chained Equations in R," Journal of Statistical Software, Foundation for Open Access Statistics, vol. 45(i03).
    2. Don Husereau & Michael Drummond & Stavros Petrou & Chris Carswell & David Moher & Dan Greenberg & Federico Augustovski & Andrew Briggs & Josephine Mauskopf & Elizabeth Loder, 2013. "Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement," PharmacoEconomics, Springer, vol. 31(5), pages 361-367, May.
    3. Nicholas R. Latimer, 2013. "Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data," Medical Decision Making, , vol. 33(6), pages 743-754, August.
    4. Anirban Basu & Andrea Manca, 2012. "Regression Estimators for Generic Health-Related Quality of Life and Quality-Adjusted Life Years," Medical Decision Making, , vol. 32(1), pages 56-69, January.
    5. Wei Pan, 2001. "Akaike's Information Criterion in Generalized Estimating Equations," Biometrics, The International Biometric Society, vol. 57(1), pages 120-125, March.
    6. Elisabeth Fenwick & Karl Claxton & Mark Sculpher, 2001. "Representing uncertainty: the role of cost‐effectiveness acceptability curves," Health Economics, John Wiley & Sons, Ltd., vol. 10(8), pages 779-787, December.
    7. Putter, Hein, 2011. "Special Issue about Competing Risks and Multi-State Models," Journal of Statistical Software, Foundation for Open Access Statistics, vol. 38(i01).
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Saha, Sanjib & Gerdtham, Ulf-G. & Toresson, Håkan & Minthon, Lennart & Jarl, Johan, 2018. "Economic Evaluation of Nonpharmacological Interventions for Dementia Patients and their Caregivers - A Systematic Literature Review," Working Papers 2018:10, Lund University, Department of Economics.
    2. Rachel Elliott & Koen Putman & Matthew Franklin & Lieven Annemans & Nick Verhaeghe & Martin Eden & Jasdeep Hayre & Sarah Rodgers & Aziz Sheikh & Anthony Avery, 2014. "Cost Effectiveness of a Pharmacist-Led Information Technology Intervention for Reducing Rates of Clinically Important Errors in Medicines Management in General Practices (PINCER)," PharmacoEconomics, Springer, vol. 32(6), pages 573-590, June.
    3. Yates, Brian T., 2021. "Toward collaborative cost-inclusive evaluation: Adaptations and transformations for evaluators and economists," Evaluation and Program Planning, Elsevier, vol. 89(C).
    4. Geronimi, J. & Saporta, G., 2017. "Variable selection for multiply-imputed data with penalized generalized estimating equations," Computational Statistics & Data Analysis, Elsevier, vol. 110(C), pages 103-114.
    5. Deidda, Manuela & Geue, Claudia & Kreif, Noemi & Dundas, Ruth & McIntosh, Emma, 2019. "A framework for conducting economic evaluations alongside natural experiments," Social Science & Medicine, Elsevier, vol. 220(C), pages 353-361.
    6. Giovanna Elisa Calabrò & Sara Boccalini & Donatella Panatto & Caterina Rizzo & Maria Luisa Di Pietro & Fasika Molla Abreha & Marco Ajelli & Daniela Amicizia & Angela Bechini & Irene Giacchetta & Piero, 2022. "The New Quadrivalent Adjuvanted Influenza Vaccine for the Italian Elderly: A Health Technology Assessment," IJERPH, MDPI, vol. 19(7), pages 1-14, March.
    7. Noémi Kreif & Richard Grieve & Iván Díaz & David Harrison, 2015. "Evaluation of the Effect of a Continuous Treatment: A Machine Learning Approach with an Application to Treatment for Traumatic Brain Injury," Health Economics, John Wiley & Sons, Ltd., vol. 24(9), pages 1213-1228, September.
    8. Abhilash Bandam & Eedris Busari & Chloi Syranidou & Jochen Linssen & Detlef Stolten, 2022. "Classification of Building Types in Germany: A Data-Driven Modeling Approach," Data, MDPI, vol. 7(4), pages 1-23, April.
    9. Saha, Sanjib & Gerdtham, Ulf-G. & Toresson, Håkan & Minthon, Lennart & Jarl, Johan, 2018. "Economic Evaluation of Interventions for Screening of Dementia," Working Papers 2018:20, Lund University, Department of Economics.
    10. Boonstra Philip S. & Little Roderick J.A. & West Brady T. & Andridge Rebecca R. & Alvarado-Leiton Fernanda, 2021. "A Simulation Study of Diagnostics for Selection Bias," Journal of Official Statistics, Sciendo, vol. 37(3), pages 751-769, September.
    11. Lin Lin & Rachel L Spreng & Kelly E Seaton & S Moses Dennison & Lindsay C Dahora & Daniel J Schuster & Sheetal Sawant & Peter B Gilbert & Youyi Fong & Neville Kisalu & Andrew J Pollard & Georgia D Tom, 2024. "GeM-LR: Discovering predictive biomarkers for small datasets in vaccine studies," PLOS Computational Biology, Public Library of Science, vol. 20(11), pages 1-23, November.
    12. Wei Pan, 2001. "Model Selection in Estimating Equations," Biometrics, The International Biometric Society, vol. 57(2), pages 529-534, June.
    13. Christopher J Greenwood & George J Youssef & Primrose Letcher & Jacqui A Macdonald & Lauryn J Hagg & Ann Sanson & Jenn Mcintosh & Delyse M Hutchinson & John W Toumbourou & Matthew Fuller-Tyszkiewicz &, 2020. "A comparison of penalised regression methods for informing the selection of predictive markers," PLOS ONE, Public Library of Science, vol. 15(11), pages 1-14, November.
    14. Liangyuan Hu & Lihua Li, 2022. "Using Tree-Based Machine Learning for Health Studies: Literature Review and Case Series," IJERPH, MDPI, vol. 19(23), pages 1-13, December.
    15. Norah Alyabs & Sy Han Chiou, 2022. "The Missing Indicator Approach for Accelerated Failure Time Model with Covariates Subject to Limits of Detection," Stats, MDPI, vol. 5(2), pages 1-13, May.
    16. Feldkircher, Martin, 2014. "The determinants of vulnerability to the global financial crisis 2008 to 2009: Credit growth and other sources of risk," Journal of International Money and Finance, Elsevier, vol. 43(C), pages 19-49.
    17. Vens, Maren & Ziegler, Andreas, 2012. "Generalized estimating equations and regression diagnostics for longitudinal controlled clinical trials: A case study," Computational Statistics & Data Analysis, Elsevier, vol. 56(5), pages 1232-1242.
    18. repec:plo:pone00:0154450 is not listed on IDEAS
    19. Clarke, Lorcan, 2020. "An introduction to economic studies, health emergencies, and COVID-19," LSE Research Online Documents on Economics 105051, London School of Economics and Political Science, LSE Library.
    20. Najmiatul Fitria & Antoinette D. I. Asselt & Maarten J. Postma, 2019. "Cost-effectiveness of controlling gestational diabetes mellitus: a systematic review," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(3), pages 407-417, April.
    21. Qi Cao & Erik Buskens & Hans L. Hillege & Tiny Jaarsma & Maarten Postma & Douwe Postmus, 2019. "Stratified treatment recommendation or one-size-fits-all? A health economic insight based on graphical exploration," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(3), pages 475-482, April.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0269192. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.